The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study-Reference-Cited by-同舟云学术

The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study

Published:2019-11-20 Issue:4 Volume:17 Page:495-502
ISSN:1738-1088
Container-title:Clinical Psychopharmacology and Neuroscience
language:en
Short-container-title:Clin Psychopharmacol Neurosci

Author:

Han Changsu¹^ORCID,Wang Sheng-Min²³^ORCID,Bahk Won-Myong²^ORCID,Lee Soo-Jung²^ORCID,Patkar Ashwin A.⁴^ORCID,Masand Prakash S.⁵^ORCID,Pae Chi-Un²⁴⁶^ORCID

Affiliation:

1. Department of Psychiatry, Korea University College of Medicine, Seoul, Korea

2. Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea

3. International Health Care Center, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

4. Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA

5. Global Medical Education, New York, NY, USA

6. Cell Death Disease Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea

Funder

Otsuka Pharmaceutical

Publisher

Korean College of Neuropsychopharmacology

Subject

Pharmacology (medical),Behavioral Neuroscience,Psychiatry and Mental health

Link

http://pdf.medrang.co.kr/CPN2/2019/017/cpn017-04-04.pdf

Reference44 articles.

1. STAR*D: What Have We Learned?

2. Dose Trends of Aripiprazole from 2004 to 2014 in Psychiatric Inpatients in Korea

3. A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial

4. Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter study

5. The prevalence and illness characteristics of DSM-5-defined “mixed feature specifier” in adults with major depressive disorder and bipolar disorder: Results from the International Mood Disorders Collaborative Project

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Potential Role of Aripiprazole Augmentation for Major Depressive Disorder with Anxious Distress in Naturalistic Treatment Setting;Clinical Psychopharmacology and Neuroscience;2024-02-04

2. Additional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting;Clinical Psychopharmacology and Neuroscience;2023-08-31

3. Use of the Third-Generation Atypical Antipsychotic Aripiprazole (Zylaxera®) for Treatment of Depressive States in Schizophrenia: Efficacy and Safety Study;Psikhiatriya;2023-06-19

4. Можливості фармакотерапії постінсультної депресії: новий погляд на стару проблему;INTERNATIONAL NEUROLOGICAL JOURNAL;2023-02-13

5. The Korean Medication Algorithm Project for Depressive Disorder (KMAP-DD): Changes in Preferred Treatment Strategies and Medications over 20 Years and Five Editions;Journal of Clinical Medicine;2023-02-01